1Z
1ZL.F Zai Lab Limited
- Market cap
- EUR 2.90B
- P/E
- -
- P/B
- 5.72x
- ROE
- -35.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 1ZL.F undervalued?
Graham numberThe Graham number of Zai Lab Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zai Lab Limited fundamental analysis
No fundamental analysis for Zai Lab Limited yet.
Zai Lab Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zai Lab Limited
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropa…
Full company profileZai Lab Limited financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zai Lab Limited annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 0.00 | 129K | 13.0M | 49.0M | 144M | 215M | 267M | 399M | 460M | 419M |
| Gross Profit | 0.00 | 0.00 | 85.9K | 9.24M | 32.2M | 92.1M | 141M | 171M | 251M | 269M | 235M |
| Operating Income | -38.5M | -51.4M | -142M | -203M | -302M | -700M | -404M | -374M | -274M | -224M | -278M |
| EBITDA | - | -50.8M | -137M | -190M | -263M | -697M | -443M | -326M | -243M | -158M | -176M |
| Net Income | -37.5M | -50.4M | -139M | -195M | -269M | -704M | -443M | -335M | -257M | -176M | -197M |
| EPS | - | -1.01 | -2.38 | -2.85 | -3.06 | -7.38 | -0.46 | -0.34 | -0.24 | -0.16 | -0.17 |
| Balance Sheet | |||||||||||
| Total Assets | 88.9M | 250M | 302M | 355M | 1.30B | 1.61B | 1.22B | 1.04B | 1.19B | 1.17B | 1.02B |
| Total Liabilities | 140M | 14.5M | 50.9M | 60.5M | 128M | 230M | 175M | 240M | 345M | 457M | 461M |
| Shareholders' Equity | -51.6M | 235M | 251M | 295M | 1.17B | 1.38B | 1.05B | 796M | 841M | 716M | 563M |
| Cash & Short-term Investments | 83.9M | 230M | 63.0M | 75.9M | 442M | 964M | 1.01B | 790M | 450M | 680M | 550M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -32.2M | -32.4M | -97.5M | -191M | -216M | -549M | -368M | -198M | -215M | -151M | -178M |
| Capital Expenditure | 2.23M | 9.10M | 10.0M | 6.04M | 10.1M | 18.3M | 24.6M | 8.49M | 61.5M | 13.4M | 48.9M |
| Free Cash Flow | - | -41.5M | -108M | -206M | -227M | -568M | -393M | -207M | -276M | -164M | -226M |
| Ratios | |||||||||||
| ROE | - | -21.4% | -55.4% | -66.2% | -23.0% | -51.1% | -42.4% | -42.0% | -30.6% | -24.5% | -35.0% |
| ROA | -42.2% | -20.2% | -46.1% | -54.9% | -20.7% | -43.8% | -36.3% | -32.3% | -21.7% | -15.0% | -19.3% |
| Net Profit Margin | - | - | -107,433.6% | -1,502.3% | -549.3% | -488.2% | -206.1% | -125.5% | -64.4% | -38.1% | -47.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Zai Lab Limited dividends
Zai Lab Limited has not paid dividends in the last 9 fiscal years.
Who owns Zai Lab Limited
- Insiders 1.93%
- Institutions 33.50%
- Public & others 64.57%
- Shares outstanding 124M
- Free float 97.3M
Zai Lab Limited company profile
- Company name
- Zai Lab Limited
- Ticker
- 1ZL.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,784
- Fiscal year end
- December
- Address
- Building B, Pudong, China, 201203
- Phone
- 86 21 6163 2588
- Website
- zailaboratory.com
About Zai Lab Limited
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
Zai Lab Limited management
9- Dr. Ying Du Ph.D.Founder, Chairperson & CEO · born 1966
- Dr. Rafael G. Amado M.D.President and Head of Global Research & Development · born 1964
- Dr. Yajing Chen Ph.D.Chief Financial Officer · born 1968
- Mr. Frazor Titus Edmondson III, J.D.Chief Legal Officer & Corporate Secretary · born 1966
- Ms. Christine ChiouSenior VP & Head of Investor Relations
- Shaun MaccounExecutive Director of Global Communications
- Dr. James Yan DABT, M.D., Ph.D.Chief Operating Officer of Global R&D · born 1964
- Dr. Shan He Ph.D.Senior VP & Chief Business Officer
- Xiaoyu ChenExecutive Director of Regional Communications